FindTrial
Sign In

SBP-101

DRUG4 trials

Sponsors

Panbela Therapeutics Inc., Panbela Therapeutics, Inc.

Conditions

Ductal Adenocarcinoma of the PancreasMetastatic Pancreatic Ductal AdenocarcinomaPancreatic CancerPancreatic Cancer MetastaticPancreatic Cancer Stage IVPancreatic Ductal AdenocarcinomaStage IV Pancreatic Cancer

Phase 1

Study of SBP-101 in Pancreatic Cancer
CompletedNCT02657330
Panbela Therapeutics, Inc.Ductal Adenocarcinoma of the Pancreas, Pancreatic Cancer
Start: 2016-01-31End: 2017-10-31Updated: 2018-04-20
Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
CompletedNCT03412799
Panbela Therapeutics, Inc.Pancreatic Cancer Metastatic, Pancreatic Cancer Stage IV, Stage IV Pancreatic Cancer
Start: 2018-06-04End: 2022-02-28Updated: 2022-05-25

Phase 2

Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
RecruitingNCT05254171
Panbela Therapeutics, Inc.Pancreatic Cancer Metastatic, Pancreatic Cancer Stage IV, Pancreatic Ductal Adenocarcinoma
Start: 2022-08-08End: 2027-01-01Target: 600Updated: 2024-11-06
A Randomized, Double-Blind, Placebo-Controlled Study of Nab-Paclitaxel and Gemcitabine With Or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma
CompletedCTIS2024-514714-12-00
Panbela Therapeutics Inc.Metastatic Pancreatic Ductal Adenocarcinoma
Start: 2022-11-11End: 2025-03-28Target: 407Updated: 2024-11-28

Related Papers

Efficacy of SBP-101, a polyamine metabolic inhibitor, administered in combination with gemcitabine and nab-paclitaxel, as a first-line treatment for patients with metastatic pancreatic ductal adenocarcinoma.
Journal of Clinical Oncology2022-01-191 citations
SBP-101, a polyamine metabolic inhibitor, administered in combination with gemcitabine and nab-paclitaxel, shows signals of efficacy as first-line treatment for subjects with metastatic pancreatic ductal adenocarcinoma.
Journal of Clinical Oncology2021-05-206 citations
Efficacy of SBP-101, in combination with gemcitabine and nab-paclitaxel, in first-line treatment of metastatic pancreatic ductal adenocarcinoma.
Journal of Clinical Oncology2020-02-01
A phase 1 safety study of SBP-101, a polyamine metabolic inhibitor, for pancreatic ductal adenocarcinoma (PDA).
Journal of Clinical Oncology2018-05-203 citations